Estimation of ENPP1 deficiency genetic prevalence using a comprehensive literature review and population databases.
Autosomal recessive hypophosphatemic rickets type 2 (ARHR2)
ENPP1 deficiency
Generalized arterial calcification of infancy (GACI)
Population database
Prevalence
Journal
Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602
Informations de publication
Date de publication:
02 12 2022
02 12 2022
Historique:
received:
08
08
2022
accepted:
20
11
2022
entrez:
2
12
2022
pubmed:
3
12
2022
medline:
7
12
2022
Statut:
epublish
Résumé
ENPP1 Deficiency-caused by biallelic variants in ENPP1-leads to widespread arterial calcification in early life (Generalized Arterial Calcification of Infancy, GACI) or hypophosphatemic rickets in later life (Autosomal Recessive Hypophosphatemic Rickets type 2, ARHR2). A prior study using the Exome Aggregation Consortium (ExAC)-a database of exomes obtained from approximately 60,000 individuals-estimated the genetic prevalence at approximately 1 in 200,000 pregnancies. We estimated the genetic prevalence of ENPP1 Deficiency by evaluating allele frequencies from a population database, assuming Hardy-Weinberg equilibrium. This estimate benefitted from a comprehensive literature review using Mastermind ( https://mastermind.genomenon.com/ ), which uncovered additional variants and supporting evidence, a larger population database with approximately 140,000 individuals, and improved interpretation of variants as per current clinical guidelines. We estimate a genetic prevalence of approximately 1 in 64,000 pregnancies, thus more than tripling the prior estimate. In addition, the carrier frequency of ENPP1 variants was found to be highest in East Asian populations, albeit based on a small sample. These results indicate that a significant number of patients with ENPP1 Deficiency remain undiagnosed. Efforts to increase disease awareness as well as expand genetic testing, particularly in non-European populations are warranted, especially now that clinical trials for enzyme replacement therapy, which proved successful in animal models, are underway.
Sections du résumé
BACKGROUND
ENPP1 Deficiency-caused by biallelic variants in ENPP1-leads to widespread arterial calcification in early life (Generalized Arterial Calcification of Infancy, GACI) or hypophosphatemic rickets in later life (Autosomal Recessive Hypophosphatemic Rickets type 2, ARHR2). A prior study using the Exome Aggregation Consortium (ExAC)-a database of exomes obtained from approximately 60,000 individuals-estimated the genetic prevalence at approximately 1 in 200,000 pregnancies.
METHODS
We estimated the genetic prevalence of ENPP1 Deficiency by evaluating allele frequencies from a population database, assuming Hardy-Weinberg equilibrium. This estimate benefitted from a comprehensive literature review using Mastermind ( https://mastermind.genomenon.com/ ), which uncovered additional variants and supporting evidence, a larger population database with approximately 140,000 individuals, and improved interpretation of variants as per current clinical guidelines.
RESULTS
We estimate a genetic prevalence of approximately 1 in 64,000 pregnancies, thus more than tripling the prior estimate. In addition, the carrier frequency of ENPP1 variants was found to be highest in East Asian populations, albeit based on a small sample.
CONCLUSION
These results indicate that a significant number of patients with ENPP1 Deficiency remain undiagnosed. Efforts to increase disease awareness as well as expand genetic testing, particularly in non-European populations are warranted, especially now that clinical trials for enzyme replacement therapy, which proved successful in animal models, are underway.
Identifiants
pubmed: 36461014
doi: 10.1186/s13023-022-02577-2
pii: 10.1186/s13023-022-02577-2
pmc: PMC9717445
doi:
Types de publication
Review
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
421Informations de copyright
© 2022. The Author(s).
Références
PLoS Genet. 2022 Apr 28;18(4):e1010192
pubmed: 35482848
Nucleic Acids Res. 2014 Dec 16;42(22):13534-44
pubmed: 25416802
Nucleic Acids Res. 2020 Jan 8;48(D1):D835-D844
pubmed: 31777943
NPJ Genom Med. 2021 Jun 2;6(1):41
pubmed: 34078906
Nucleic Acids Res. 2012 Jul;40(Web Server issue):W452-7
pubmed: 22689647
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
Clin Genet. 2015 Jun;87(6):570-5
pubmed: 24813812
Nat Commun. 2015 Dec 01;6:10006
pubmed: 26624227
Curr Protoc Hum Genet. 2013 Jan;Chapter 7:Unit7.20
pubmed: 23315928
J Bone Miner Res. 2022 Jun;37(6):1125-1135
pubmed: 35340077
Kidney Int. 2014 Jun;85(6):1351-6
pubmed: 24717293
Circ Cardiovasc Genet. 2008 Dec;1(2):133-40
pubmed: 20016754
Genet Med. 2016 Jan;18(1):41-8
pubmed: 25764212
Science. 1908 Jul 10;28(706):49-50
pubmed: 17779291
J Bone Miner Res. 2022 Mar;37(3):494-504
pubmed: 34882836
Nature. 2020 May;581(7809):434-443
pubmed: 32461654
Hum Mutat. 2016 Jun;37(6):564-9
pubmed: 26931183
Dis Model Mech. 2018 Oct 8;11(10):
pubmed: 30158213
Nucleic Acids Res. 2017 Jan 4;45(D1):D840-D845
pubmed: 27899611
J Bone Miner Res. 2022 Feb;37(2):202-214
pubmed: 34633109
J Bone Miner Res. 2020 Mar;35(3):528-539
pubmed: 31805212
Front Genet. 2020 Nov 13;11:577152
pubmed: 33281875
Nat Methods. 2014 Apr;11(4):361-2
pubmed: 24681721
Am J Physiol Heart Circ Physiol. 2011 Jul;301(1):H61-8
pubmed: 21490328
Genet Med. 2021 Feb;23(2):396-407
pubmed: 33005041